Differential intercellular transmission efficiency of misfolded proteins (tau, α-synuclein, TDP-43) is determined by their distinct conformational epitopes that preferentially engage specific heparan sulfate proteoglycan (HSPG) subtypes on target cells. While tau and α-synuclein form incipient conformers with high-affinity HSPG binding motifs accessible for rapid endocytic uptake, TDP-43 adopts conformations with reduced HSPG affinity, resulting in slower uptake kinetics. Syndecan-3 and glypican-1 preferentially mediate tau and α-synuclein transmission respectively, whereas TDP-43 transmission relies more heavily on alternative pathways such as galectin-3-mediated macropinocytosis. Blocking HSPG-mediated uptake will preferentially inhibit tau and α-synuclein transmission while having minimal effect on TDP-43, confirming selectivity in transmission mechanisms. This mechanism predicts that heparin or HS mimetics will differentially suppress transmission in a protein-specific manner.
Curated pathway from expert analysis
flowchart TD
A["SDC3 Syndecan-3<br/>Heparan Sulfate Proteoglycan"]
B["Misfolded Protein<br/>Binding Selectivity"]
C["Endocytosis<br/>Efficiency"]
D["Protein Transmission<br/>Propagation"]
E["SDC3 as<br/>Transmission Efficiency Target"]
F["HSPG-Based<br/>Therapeutic Strategy"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for SDC3 yet. Search RCSB →
Median TPM across 13 brain regions for SDC3 (Syndecan-3) from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SDC3 (Syndecan-3).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF Syndecan-3 (SDC3) is selectively knocked down using CRISPR/Cas9 or siRNA in acceptor neurons, THEN tau (but not TDP-43) transmission efficiency will decrease by ≥40% relative to non-targeting contr | SDC3 knockdown acceptor cells will show tau uptake at ≤60% of control levels; TDP-43 uptake will remain ≥85% of control. Conversely, GPC1 knockdown will reduce | — no observation — | pending | 0.70 |
| IF primary neurons or induced pluripotent stem cell (iPSC)-derived neurons are treated with heparin (10 μg/mL) or a heparan sulfate mimetic (Fengycin or PG545 at 5 μM) to block HSPG-mediated endocytos | Tau transmission efficiency (measured by flow cytometry for acceptor cell uptake of donor-derived protein, or by Live Imaging of cytoplasm-to-cytoplasm transfer | — no observation — | pending | 0.75 |